MEMO FROM DR. LEN SANDS OF THE SAN DIEGO
A Comprehensive Perspective of CMO May 1999 as an Adaptagenic
Immunomodulator by Dr. Len Sands
CMO is the world's first and only true adaptagenic immunomodulator.
Only CMO has corrective and restorative immunomodulatory properties
auto immune disease. Other so-called "immunomodulators"
do not. They
function primarily as immunosuprressants or immunostimulants. They
capable of only one principal action, either suppressing or stimulating
function. CMO, on the other hand, permanently corrects autoimmune
programs within the memory T-cells themselves rather than just temporarily
suppressing or stimulating immune system activities. That is why a
CMO therapy program usually lasts forever without any need to repeat
therapy or use any additional medication of any kind.
CMO is not an immunosuppressant, nor an immuostimulant. Nor is it
pharmaceutical. It is a naturally derived substance that has received
safety level by certified independent laboratory testing.
Some practitioners have theorized that, in the case of arthritis for
CMO merely acts upon pain receptors at the arthritis site. If that
CMO's effects would not be permanent. Furthermore, that theory cannot
how CMO lowers blood sedimentation rates in Lupus patients,
or how it reverses lung inflammation in emphysema,
or how it lowers the need for insulin in diabetics
or how it reverses prostate inflammation
or how it relieves certain symptoms of multiple sclerosis,
or how it corrects Crohn's disease,
or how it reverses fibromyalia
or how it lowers high blood pressure yet elevates low blood pressure
or how it benefits virtually any ailment with auto immune components
Obviously, CMO is a general remedial immunomodulator that acts upon
memory T-cells which control the autoimmune processes within our bodies.
Those who speculate otherwise have misunderstood the biophysiological
actions of CMO within the body.
It is also important to understand that CMO acts only upon the memory
T-cells and does not inhibit the activities of any of the several
other types of
T-cells that are responsible for combating infective microorganisms
Unlike the immunosuppressants commonly used to try to temporarily
symptoms of autoimmune diseases, CMO does not leave the body
vulnerable to attack by disease-causing agents. Nor does it inhibit
resistance to tumor formation, as do the dangerous new tumor necrosis
(TNF) suppressants of some new arthritis drugs.
Copyright 1999 Dr. L. Sands. All rights reserved.
NO DOUBLE BLIND, PLACEBO CONTROLLED TESTS HAVE
BEEN DONE ON HUMANS. ALL BENEFITS FROM Original CMO ON PEOPLE WITH
FIBROMYALGIA IS ANECDOTAL.
The CMO Fibro package is available at